{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:14:26Z","timestamp":1779372866289,"version":"3.53.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s41669-026-00644-z","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:07:25Z","timestamp":1775070445000},"page":"407-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-2612","authenticated-orcid":false,"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-2813","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-0936","authenticated-orcid":false,"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-1731","authenticated-orcid":false,"given":"Sanjana","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin H.","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-6467","authenticated-orcid":false,"given":"Salini","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-2315","authenticated-orcid":false,"given":"Matthew S.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"9693","key":"644_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O'Brien","year":"2009","unstructured":"O\u2019Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893\u2013902.","journal-title":"Lancet"},{"issue":"7","key":"644_CR2","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl B, O\u2019Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315. Lancet Glob Health. 2018Jul;6(7):e744\u201357.","journal-title":"Lancet Glob Health"},{"key":"644_CR3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22341.1","author":"C Feldman","year":"2020","unstructured":"Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res. 2020. https:\/\/doi.org\/10.12688\/f1000research.22341.1.","journal-title":"F1000Res"},{"key":"644_CR4","unstructured":"Gierke R, Wodi P, Kobayashi M. Epidemiology and prevention of vaccine-preventable disease. Vol. Chapter 17-Pneumoococcal Disease. 14th Edition (2021) ed: CDC."},{"issue":"2","key":"644_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11136-021-02941-y","volume":"1","author":"R O'Reilly","year":"2022","unstructured":"O\u2019Reilly R, Yokoyama S, Boyle J, et al. The impact of acute pneumococcal disease on health state utility values: a systematic review. Qual Life Res. 2022;1(2):375\u201388.","journal-title":"Qual Life Res"},{"issue":"1","key":"644_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41479-023-00110-y","volume":"15","author":"KL Kruckow","year":"2023","unstructured":"Kruckow KL, Zhao K, Bowdish DME, et al. Acute organ injury and long-term sequelae of severe pneumococcal infections. Pneumonia (Nathan). 2023;15(1):5.","journal-title":"Pneumonia (Nathan)."},{"issue":"1","key":"644_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","volume":"17","author":"MJ Mangen","year":"2017","unstructured":"Mangen MJ, Huijts SM, Bonten MJ, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"644_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, et al. systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"key":"644_CR9","unstructured":"FDA label for pneumococcal 15-valent conjugate vaccine. Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-VAXNEUVANCE.pdf."},{"key":"644_CR10","unstructured":"FDA label for pneumococcal 20-valent conjugate vaccine Available from: https:\/\/www.fda.gov\/media\/149987\/download."},{"key":"644_CR11","unstructured":"FDA label for pneumococcal 15-valent conjugate vaccine. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxneuvance."},{"key":"644_CR12","unstructured":"EMA label for pneumococcal 20-valent conjugate vaccine. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-20-previously-apexxnar"},{"key":"644_CR13","unstructured":"CDC-Recommended Vaccines for Adults. Available from: https:\/\/www.cdc.gov\/pneumococcal\/vaccines\/adults.html."},{"issue":"11","key":"644_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, Khan K, Keaney K, et al. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health."},{"issue":"2","key":"644_CR15","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1093\/pubmed\/fdab159","volume":"44","author":"Z Tang","year":"2022","unstructured":"Tang Z, Matanock A, Jeon S, et al. A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease. J Public Health (Oxf). 2022;44(2):e234\u201340.","journal-title":"J Public Health (Oxf)"},{"issue":"9","key":"644_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40273-025-01504-0","volume":"43","author":"M Huang","year":"2025","unstructured":"Huang M, Xie J, Romdhani H, et al. Global assessment of health utilities associated with pneumococcal disease in children-targeted literature reviews. Pharmacoeconomics. 2025;43(9):1001\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"644_CR17","first-page":"5","volume":"10","author":"M Huang","year":"2025","unstructured":"Huang M, Xie J, Romdhani H, et al. Global assessment of health utilities associated with pneumococcal disease in adults: targeted literature reviews. Pharmacoecon Open. 2025;10(10):5\u201333.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"644_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2257426","volume":"19","author":"D Lytle","year":"2023","unstructured":"Lytle D, Grajales Beltran AG, Perdrizet J, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023;19(2):2257426.","journal-title":"Hum Vaccin Immunother"},{"issue":"18","key":"644_CR19","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","volume":"41","author":"N Prasad","year":"2023","unstructured":"Prasad N, Stoecker C, Xing W, et al. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States. Vaccine. 2023;41(18):2914\u201321.","journal-title":"Vaccine"},{"key":"644_CR20","unstructured":"Systematic Reviews: CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination; 2009."},{"key":"644_CR21","unstructured":"Institute of Medicine (US) Committee to Study Priorities for Vaccine Development. Vaccines for the 21st Century: A Tool for Decisionmaking. In: Stratton K, Durch J, Lawrence R, editors. National Academies Press (US); 2000."},{"issue":"4","key":"644_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0030-6665(20)31103-8","volume":"24","author":"MV Goycoolea","year":"1991","unstructured":"Goycoolea MV, Hueb MM, Ruah C. Otitis media: the pathogenesis approach. Definitions and terminology. Otolaryngol Clin North Am. 1991;24(4):757\u201361.","journal-title":"Otolaryngol Clin North Am"},{"issue":"5","key":"644_CR23","first-page":"2117","volume":"45","author":"DA Randall","year":"1992","unstructured":"Randall DA, Fornadley JA, Kennedy KS. Management of recurrent otitis media. Am Fam Physician. 1992;45(5):2117\u201323.","journal-title":"Am Fam Physician"},{"key":"644_CR24","unstructured":"NICE technology appraisal and highly specialised technologies guidance: the manual 2025. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741."},{"issue":"1","key":"644_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"16","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;16(1):54.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"644_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/hec.4131","volume":"29","author":"SA Lipman","year":"2020","unstructured":"Lipman SA, Brouwer WBF, Attema AE. What is it going to be, TTO or SG? A direct test of the validity of health state valuation. Health Econ. 2020;29(11):1475\u201381.","journal-title":"Health Econ"},{"issue":"3","key":"644_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"2","key":"644_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1542\/peds.113.2.283","volume":"113","author":"LA Prosser","year":"2004","unstructured":"Prosser LA, Ray GT, O\u2019Brien M, et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113(2):283\u201390.","journal-title":"Pediatrics"},{"key":"644_CR29","volume-title":"Disability weights for diseases in the Netherlands","author":"MEA Stouthard","year":"1997","unstructured":"Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al. Disability weights for diseases in the Netherlands. University of Amsterdam; 1997."},{"issue":"6","key":"644_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","volume":"36","author":"MR Gold","year":"1998","unstructured":"Gold MR, Franks P, McCoy KI, et al. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778\u201392.","journal-title":"Med Care"},{"issue":"14","key":"644_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/archinte.1996.00440130115012","volume":"156","author":"CM Coley","year":"1996","unstructured":"Coley CM, Li YH, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156(14):1565\u201371.","journal-title":"Arch Intern Med"},{"issue":"5","key":"644_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"MJ Mangen","year":"2015","unstructured":"Mangen MJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316.","journal-title":"Eur Respir J"},{"issue":"5","key":"644_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139.","journal-title":"Clin Infect Dis"},{"issue":"339","key":"644_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2688","volume":"22","author":"D Arnold","year":"2009","unstructured":"Arnold D, Girling A, Stevens A, et al. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;22(339):b2688.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"644_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","volume":"35","author":"D Rowen","year":"2017","unstructured":"Rowen D, Azzabi Zouraq I, Chevrou-Severac H, et al. International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics. 2017;35(Suppl 1):11\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"644_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245\u201357.","journal-title":"Eur J Health Econ"},{"issue":"31\u201332","key":"644_CR37","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","volume":"22","author":"A Melegaro","year":"2004","unstructured":"Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31\u201332):4203\u201314.","journal-title":"Vaccine"},{"key":"644_CR38","doi-asserted-by":"crossref","unstructured":"Erickson P, Wilson R, Shannon I. Statistical notes no. 7: Years of healthy life. Healthy People 2000 Stat Notes. 1995 (1995\/04\/01).","DOI":"10.1037\/e583992012-001"},{"key":"644_CR39","doi-asserted-by":"crossref","unstructured":"Torrance GW, Erickson P, Patrick DL, et al. Technical notes. In: Erickson P, Wilson R, Shannon I. Statistical notes no. 7: Years of healthy life. Healthy People 2000 Stat Notes. 1995 (1995\/04\/01).","DOI":"10.1037\/e583992012-001"},{"issue":"1","key":"644_CR40","first-page":"43","volume":"154","author":"JE Bennett","year":"2000","unstructured":"Bennett JE, Sumner W 2nd, Downs SM, et al. Parents\u2019 utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"644_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1155\/2007\/713576","volume":"18","author":"A Morrow","year":"2007","unstructured":"Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121\u20137.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"644_CR42","first-page":"37","volume":"20","author":"GW Torrance","year":"1982","unstructured":"Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med. 1982;20:37\u201345.","journal-title":"Mead Johnson Symp Perinat Dev Med"},{"issue":"9","key":"644_CR43","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40273-018-0670-1","volume":"36","author":"S Petrou","year":"2018","unstructured":"Petrou S, Kwon J, Madan J. A practical guide to conducting a systematic review and meta-analysis of health state utility values. Pharmacoeconomics. 2018;36(9):1043\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"644_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1542\/peds.93.5.697","volume":"93","author":"MS Kramer","year":"1994","unstructured":"Kramer MS, Etezadi-Amoli J, Ciampi A, et al. Parents\u2019 versus physicians\u2019 values for clinical outcomes in young febrile children. Pediatrics. 1994;93(5):697\u2013702.","journal-title":"Pediatrics"},{"issue":"3","key":"644_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0272989X08327398","volume":"29","author":"S Petrou","year":"2009","unstructured":"Petrou S, Kupek E. Estimating preference-based health utilities index mark 3 utility scores for childhood conditions in England and Scotland. Med Decis Making. 2009;29(3):291\u2013303.","journal-title":"Med Decis Making"},{"issue":"5 Suppl 1","key":"644_CR46","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","volume":"14","author":"J Galante","year":"2011","unstructured":"Galante J, Augustovski F, Colantonio L, et al. Estimation and comparison of EQ-5D health states\u2019 utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health. 2011;14(5 Suppl 1):S60\u20134.","journal-title":"Value Health."},{"issue":"13","key":"644_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2431-13-122","volume":"13","author":"W Kulpeng","year":"2013","unstructured":"Kulpeng W, Sornsrivichai V, Chongsuvivatwong V, et al. Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC Pediatr. 2013;13(13):122.","journal-title":"BMC Pediatr"},{"issue":"1","key":"644_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0149-2918(96)80188-3","volume":"18","author":"PI Oh","year":"1996","unstructured":"Oh PI, Maerov P, Pritchard D, et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18(1):160\u201382.","journal-title":"Clin Ther"},{"issue":"1","key":"644_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","volume":"155","author":"AE Carroll","year":"2009","unstructured":"Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21\u20135 (25.e1-5).","journal-title":"J Pediatr"},{"issue":"1","key":"644_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40801-016-0099-9","volume":"4","author":"B Crawford","year":"2017","unstructured":"Crawford B, Hashim SS, Prepageran N, et al. Impact of pediatric acute otitis media on child and parental quality of life and associated productivity loss in Malaysia: a prospective observational study. Drugs Real World Outcomes. 2017;4(1):21\u201331.","journal-title":"Drugs Real World Outcomes"},{"issue":"2","key":"644_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1542\/peds.2004-0778","volume":"115","author":"CN Brouwer","year":"2005","unstructured":"Brouwer CN, Maill\u00e9 AR, Rovers MM, et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics. 2005;115(2):273\u20139.","journal-title":"Pediatrics"},{"issue":"11","key":"644_CR52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1477-7525-11-201","volume":"20","author":"CH Heidemann","year":"2013","unstructured":"Heidemann CH, Godballe C, Kjeldsen AD, et al. The Otitis Media-6 questionnaire: psychometric properties with emphasis on factor structure and interpretability. Health Qual Life Outcomes. 2013;20(11):201.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"644_CR53","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/INF.0000000000000265","volume":"33","author":"T Kujala","year":"2014","unstructured":"Kujala T, Alho OP, Kristo A, et al. Quality of life after surgery for recurrent otitis media in a randomized controlled trial. Pediatr Infect Dis J. 2014;33(7):715\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"644_CR54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jama.284.7.850","volume":"284","author":"AK Cheng","year":"2000","unstructured":"Cheng AK, Rubin HR, Powe NR, et al. Cost-utility analysis of the cochlear implant in children. JAMA. 2000;284(7):850\u20136.","journal-title":"JAMA"},{"issue":"8","key":"644_CR55","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","volume":"55","author":"R Oostenbrink","year":"2002","unstructured":"Oostenbrink R, Ha AM, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"644_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.aud.0000233967.11072.24","volume":"27","author":"GR Barton","year":"2006","unstructured":"Barton GR, Stacey PC, Fortnum HM, et al. Hearing-impaired children in the United Kingdom, IV: cost-effectiveness of pediatric cochlear implantation. Ear Hear. 2006;27(5):575\u201388.","journal-title":"Ear Hear"},{"issue":"2","key":"644_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1651-2227.2003.tb00523.x","volume":"92","author":"I Koomen","year":"2003","unstructured":"Koomen I, Grobbee DE, Jennekens-Schinkel A, et al. Parental perception of educational, behavioural and general health problems in school-age survivors of bacterial meningitis. Acta Paediatr. 2003;92(2):177\u201385.","journal-title":"Acta Paediatr"},{"issue":"3","key":"644_CR58","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1651-2227.2008.01136.x","volume":"98","author":"R Legood","year":"2009","unstructured":"Legood R, Coen PG, Knox K, et al. Health related quality of life in survivors of pneumococcal meningitis. Acta Paediatr. 2009;98(3):543\u20137.","journal-title":"Acta Paediatr"},{"issue":"12","key":"644_CR59","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344.","journal-title":"Health Econ"},{"issue":"9","key":"644_CR60","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2298\/VSP160905008Z","volume":"75","author":"NDRM Zorni\u0107","year":"2018","unstructured":"Zorni\u0107 NDRM, Stojadinovi\u0107 M, Radovanovi\u0107 D, Davidovi\u0107 G, Simovi\u0107 S, Bukumiri\u0107 Z, et al. Quality of life of the mechanically ventilated patients with community-acquired pneumonia. Vojnosanit Pregl. 2018;75(9):864\u201374.","journal-title":"Vojnosanit Pregl"},{"key":"644_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-019-0481-y","volume":"5","author":"MA Lloyd","year":"2019","unstructured":"Lloyd MA, Tang CY, Callander EJ, et al. Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population. Pilot Feasibility Stud. 2019;5:97.","journal-title":"Pilot Feasibility Stud"},{"key":"644_CR62","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00012-2019","author":"LN Clausen","year":"2019","unstructured":"Clausen LN, B\u00f8rgesen M, Ravn P, et al. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study. ERJ Open Res. 2019. https:\/\/doi.org\/10.1183\/23120541.00012-2019.","journal-title":"ERJ Open Res"},{"issue":"2","key":"644_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89\u2013102.","journal-title":"Med Decis Making"},{"issue":"612","key":"644_CR64","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.3399\/bjgp13X669185","volume":"63","author":"R Oppong","year":"2013","unstructured":"Oppong R, Jit M, Smith RD, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract. 2013;63(612):e465\u201371.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"644_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10198-011-0360-9","volume":"14","author":"R Oppong","year":"2013","unstructured":"Oppong R, Kaambwa B, Nuttall J, et al. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough\/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14(2):197\u2013209.","journal-title":"Eur J Health Econ"},{"issue":"16","key":"644_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12875-015-0282-1","volume":"27","author":"J Flamaing","year":"2015","unstructured":"Flamaing J, De Backer W, Van Laethem Y, et al. Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium. BMC Fam Pract. 2015;27(16):66.","journal-title":"BMC Fam Pract"},{"issue":"650","key":"644_CR67","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.3399\/bjgp16X686533","volume":"66","author":"R Oppong","year":"2016","unstructured":"Oppong R, Smith RD, Little P, et al. Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. Br J Gen Pract. 2016;66(650):e633\u20139.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"644_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/cid\/ciaa595","volume":"73","author":"HA Glick","year":"2021","unstructured":"Glick HA, Miyazaki T, Hirano K, et al. One-year quality of life post-pneumonia diagnosis in Japanese adults. Clin Infect Dis. 2021;73(2):283\u201390.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"644_CR69","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/archotol.125.11.1214","volume":"125","author":"AK Cheng","year":"1999","unstructured":"Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"3","key":"644_CR70","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1017\/S0266462300102132","volume":"16","author":"PF Krabbe","year":"2000","unstructured":"Krabbe PF, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care. 2000;16(3):864\u201373.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"644_CR71","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/01.AUD.0000134550.80305.04","volume":"25","author":"Group UCIS","year":"2004","unstructured":"Group UCIS. Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis. Ear Hear. 2004;25(4):336\u201360.","journal-title":"Ear Hear"},{"key":"644_CR72","doi-asserted-by":"crossref","unstructured":"Lewis AT, Gergely V. Influence of bone conduction hearing implantation on health-related quality of life for patients with chronic otitis media. J Clin Med. 2022;11(18).","DOI":"10.3390\/jcm11185449"},{"issue":"8","key":"644_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MAO.0000000000003629","volume":"43","author":"BV Tailor","year":"2022","unstructured":"Tailor BV, Phillips JS, Nunney I, et al. Comparison of disease-specific, generic, and hearing-specific instruments assessing health-related quality of life in patients undergoing middle ear surgery for chronic otitis media: a prospective correlational study. Otol Neurotol. 2022;43(8):1\u201311.","journal-title":"Otol Neurotol"},{"key":"644_CR74","first-page":"3","volume":"21","author":"TYS Ikeda","year":"2017","unstructured":"Ikeda TYS, Murakami K, et al. Cost-utility analysis of a disability prevention program for community-dwelling older adults with mild disability in the urban area of Tokyo, Japan. Jpn J Human Sci Health-Soc Serv. 2017;21:3\u201312.","journal-title":"Jpn J Human Sci Health-Soc Serv."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00644-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00644-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00644-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:03:18Z","timestamp":1779372198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00644-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00644-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH, EE, and SM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc. DR is a consultant for Merck & Co., Inc. and is a member of the EuroQol group. HR, YS, and DL are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck & Co., Inc. SS was an employee of Analysis Group, Inc. at the time of study conduct. JX is an employee of XL Source, Inc., a consulting company that has provided paid consulting services to this research project. MSK is a consultant for Merck & Co., Inc. and provided paid consulting services to this research project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data\/Materials"}},{"value":"The code used in this study is not publicly available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MH, EE, and SM contributed to the conceptualization of the study. All authors contributed to the study design and methodology. HR, DL, and JX conducted the literature search and data extraction. MH and HR developed the initial summary of the results. All authors contributed to the interpretation of the findings, the development of the initial draft of the manuscript, and the revisions of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}